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Human serum inter-alpha-trypsin-inhibitor (ITI) has so far been assumed to be comprised of a single poly- 
peptide chain which can undergo fragmentation, whereby inhibitory IT1 derivatives are released into the 
blood stream. In contrast, the analysis of the baboon liver mRNA translation products howed that IT1 
is made up of heavy and light chain(s). The latter may be excreted independently and very likely 
corresponds to the so-called IT1 derivatives. 
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1. INTRODUCTION 
Inter-alpha-trypsin-inhibitor (ITI) is a serine 
protease inhibitor present in human serum as a 
180-kDa glycoprotein which consists of a single 
polypeptide chain and 8.5% carbohydrates [1,2]. 
A partial (1CkDa) amino acid sequence of ITI, 
termed HI-14, has been published; it corresponds 
to the trypsin inhibitory active part of the molecule 
which displays two tandem Kunitz-type domains 
of similar sequence (3). The primary sequence of 
IT1 outside HI-14 is not known. Physiological ITI- 
related molecules of smaller A& (IT1 derivatives) 
have been found in body fluids such as serum, 
bronchial mucus and urine [4-71; they display im- 
munological cross-reactivity with 180-kDa ITI. In 
Abbreviations: ITI, inter-alpha-trypsin inhibitor; 
HI-14/HI-30, human IT1 C-terminal (14/30 kDa) in- 
hibitory active parts; UID, urinary IT1 derivative; NHS, 
normal human serum; SDS-PAGE, sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis; CIE, crossed 
immunoelectrophoresis 
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particular, a 30-kDa molecule has been purified 
from human serum and urine; it is referred to as 
HI-30 and is basically composed of HI-14 and car- 
bohydrates [8]. An outstanding feature of IT1 is its 
possible ability to act as pro-inhibitor: as yet, 
180-kDa IT1 has been commonly considered a car- 
rier which releases IT1 derivatives into the blood 
stream [6]. 
We here report the characterization of the 
translation products from two distinct mRNAs 
coding for IT1 which both originate from baboon 
liver. These results provide new clues on the 
primary structure of IT1 and argue against the 
180-kDa IT1 being a pro-inhibitor; rather, the so- 
called IT1 derivatives may be excreted in- 
dependently after synthesis by a single mRNA 
population. 
2. MATERIALS AND METHODS 
2.1. Proteins and antisera 
Highly purified human 180-kDa IT1 devoid of 
derivatives and ITI-free human serum were 
prepared as in [9]. A urinary IT1 derivative (UID) 
of M, 43 000 has been purified from normal human 
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urine and previously characterized; it displays con- 
siderable immunological cross-reactivity with puri- 
fied HI-30 [lo]. Anti-total IT1 antiserum was made 
available [ 1 I]; it reacted with 180-kDa IT1 in serum 
and ITT derivatives in serum and urine. 
Anti-180-kDa IT1 and anti-UID antisera were 
prepared and characterized as in [lo]; the former 
reacted with the 180-kDa IT1 exclusively, whereas 
the latter reacted strondly with UID and was also 
able to bind 180-kDa IT1 at least by virtue of its 
HI-14 domain. 
2.2. Isolation of mRNAs 
Liquid nitrogen-stored liver tissue was first 
pulverized in nitrogen and then homogenized in a 
tissue grinder (Dual1 Kontes) with Tris buffer 
(200 mM Tris-HCl, pH 8.5, 250 mM sucrose, 
25 mM MgC12, 50 mM KCl, 5 mM beta-mercapto- 
ethanol, 0.5 mg/ml heparin, 4 mg/ml yeast 
tRNAs) at a ratio of 3 ml buffer/g tissue and then 
adjusted to 1% Na deoxycholate and 1% Triton 
X-100. The homogenate was centrifuged (5000 rev- 
/min, 15 min, 4”C, rotor SW27 Beckman); the 
post mitochondrial supernatant was diluted (1: 1) 
with 0.1 M Na acetate buffer (pH 5.0), 1% SDS, 
and RNAs were obtained by phenol-chloroform 
extraction. Finally, poly(A)-RNAs were purified 
by 2 successive oligo(dT)cellulose (Collaborative 
research) chromatographies [ 121 of etha- 
nol-concentrated RNAs. Fractionation of poly(A)- 
RNAs by sucrose gradient centrifugation was ac- 
complished as in [ 131. 
2.3. Cell-free translation system 
mRNA-Dependent rabbit reticulocyte lysates 
were prepared as in [14]. Translation of baboon 
mRNAs in the presence of [35S]methionine 
(Amersham) and radioactivity counting of the tri- 
chloroacetic acid-precipitable translation products 
have been detailed in [ 151. 
2.4. Immunoprecipitation on translation products 
and inhibition 
This was performed as in [ 151. Briefly, 15-20 ~1 
lysate were added with 5 ~1 antiserum sup- 
plemented or not with 10~1 inhibitor (nomal 
human serum (NHS), or purified proteins, see sec- 
tion 3); excess (20 ~1) protein A-Sepharose (Phar- 
macia) was added and the mixture was incubated 
overnight at 4°C. The protein A-bound immune 
380 
complexes were finaly eluted and further analyzed 
[151. 
2.5. Sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) 
Total translation and immunoprecipitated pro- 
ducts were analyzed by SDS-PAGE [16] in discon- 
tinuous polyacrylamide gel slabs (stacking gel 5070, 
2 cm long; cathodic separating gel 59’0, 10 cm 
long; anodic separating gel 15070, 20 cm long). 
[14C]M, markers were obtained from Amersham. 
Gel slabs were treated for fluorography [ 171. Auto- 
radiography was made on Fuji X-ray films for 
3-10 days at -80°C. 
3. RESULTS 
3. I. Immunochemical comparison of baboon 
and human ITIs 
When analyzed by crossed immunoelectrophor- 
esis with the 3 anti-IT1 antisera mentioned in sec- 
tion 2, baboon and human sera displayed a major 
1 
b ’ 
B , 0 . . 
Fig. 1. Crossed immuno-electrophoresis (CIE) of human 
(plate a) and baboon (plate b) sera. CIE was performed 
at pH 8.6 as in [lo] with an anti-total IT1 antiserum. 1st 
dimension: 7 ~1 serum, anode at right; 2nd dimension: 
2 ,A.crn-’ antiserum, anode at the top. 
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cathodic 180-kDa IT1 peak, as in [9]; furthermore, 
two anodic IT1 derivatives in partial immunologi- 
cal identity with the 180-kDa IT1 could be seen 
with anti-total IT1 (fig. 1) or anti-UID. Baboon and 
human serum ITIs differed by slower migration of 
the 180-kDa IT1 and higher amounts in IT1 deriv- 
atives in the former. A similar analysis of urine 
(not shown) indicated that baboon and human 
UIDs behaved identically with respect o immuno- 
reactivity and fast electrophoretic migration. 
Finally, baboon serum IT1 and derivatives, puri- 
fied as in [ 111, displayed M-values (175 000 for 
ITI) which were quite similar to those found for 
the human counterparts in SDS-PAGE (not 
shown). 
c 
ITI’ 
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3.2. Characterization of ITI mRNA 
translation products 
Poly(A)-RNAs from baboon liver and purified 
rabbit globin mRNAs stimulated a 15 and 30-fold 
incorporation of [35S]methionine into trichloroace- 
tic acid precipitable translation products, respec- 
tively, as compared with control translation 
without any exogenous mRNAs. 
Immunoprecipitation of the translation pro- 
ducts from baboon liver mRNAs were analyzed 
with 3 distinct anti-IT1 antisera (fig.2); in all 3 in- 
stances, inhibition of immunoprecipitation was 
performed with the same panel of human reagents 
(NHS; ITI-free serum; UID; 180-kDa ITI). Three 
polypeptide chains of 95, 90 and 40 kDa, respec- 
5% 
Fig.2. SDS-PAGE autoradiography of immunoprecipitated translation products from baboon liver mRNAs. Antisera: 
A, anti-total ITI antiserum; B, anti-180-kDa IT1 antiserum; C, anti-UID antiserum. Inhibitors: 1, none; 2, NHS; 3, 
ITI-free serum; 4, human UID; 5, human 180-kDa ITI. Left scale, M, markers (kDa); right scale, acrylamide (70. Anode 
at the bottom. 
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tively, were detected with an anti-total IT1 anti- 
serum. The two heaviest chains were bound by the 
anti-l80-kDa IT1 antiserum and not the anti-UID 
antiserum; this reaction could only be inhibited by 
the 180-kDa IT1 (or NHS). In contrast, the 40-kDa 
poly~ptide chains was bound by anti-UID anti- 
serum, this reaction being inhibited by UID and 
180-kDA ITI, whereas anti-180 kDa IT1 antiserum 
did not react with this polypeptide chain. With all 
3 anti-IT1 antisera, NHS abolished the immune 
precipitation whereas ITI-free serum did not; this 
argues that all immune precipitations are strictly 
ITI-specific. 
The 95, 90- and 40-kDa polypeptide chains cor- 
responded to 11, 1 and 88% of the radioactivity 
immunoprecipitated by anti-total ITI antiserum, 
respectively as measured by densitometry (not 
shown). When separating baboon liver mRNAs by 
centrifugation on a 5-25% sucrose gradient and 
immunoprecipitating the translation products 
from each fraction with an anti-total IT1 anti- 
serum, two populations of mRNAs emerged 
(fig.3); mRNAs coding for the 40-kDa polypeptide 
sedimented more slowly than 18 S rRNAs, whereas 
mRNAs coding for 95 and 90-kDa polypeptides 
were located near the bottom of the gradient. 
fractions 
Fig.3. Densitometric analysis of autoradiographies after 
SDS-PAGE of the translation products from two IT1 
encoding mRNAs separated by centrifugation on a 
5-25% sucrose gradient (bottom at right). (e * 06 .) 
95kDa polypeptide band. (-t-) 90-kDa poIypeptide 
band. (- -*- -) 40-kDa polypeptide band. 
4. DISCUSSION 
On biochemical and immunochemical grounds, 
the strong similarity observed between human and 
baboon IT1 and ITI derivatives prompted us to 
analyze the mRNA-dependent ranslation products 
from baboon Iiver to seek further insights on 
human IT1 biochemistry and physiology. 
IT1 is described as a single polypeptide chain 
with 8.5% carbohydrates [ 1,2]. As mRNA transla- 
tion yields unglycosylated proteins, we expected 
ITI to be translated as a single chain of about 160 
kDa. This was clearly not the case, as 3 chains of 
95, 90 and 40 kDa were obtained instead. That the 
mRNA purification and translation procedures 
were not responsible for an artefactual lack of 
heavier translation products was indicated by the 
presence of several heavy polypeptides (up to 
150 kDa) in the 5% gel in SDS-PAGE when 
analyzing the total translation products (not 
shown). The 90-kDa polypeptide represented only 
1% of the ITI-related translation products. This 
minor component may originate from cleaved 
and/or poorly translated mRNA, or represent a 
final product from the 95-kDa protein considered 
a precursor; it will not be discussed further. 
The light and major heavy IT1 polypeptide 
chains are clearly distinct: they are coded for by 
two different mRNA populations and do not 
cross-react as demonstrated by their unique reac- 
tivity with anti-UID and anit-180-kDa IT1 anti- 
sera, respectively. We can infer that the heavy 
chain is present in 180-kDa IT1 and not in UID, 
whereas the light chain is present in both UID and 
180”kDa ITI, since the latter inhibited the binding 
of anti-UID antiserum to this light chain. On the 
basis of the large similarity between light chain and 
UID, the latter containing HI-14 [lo], we can infer 
further that the light chain contains HI-14 se- 
quence; i.e., the inhibitory active part of 180-kDa 
IT1 [3]. 
The presence of two polypeptide chains with 
differing immunochemical properties encoded by 
two discrete mRNAs strongly suggests that IT1 is 
not a single polypeptide chain. We conclude now 
that the 180-kDa IT1 contains both heavy and light 
chains. Given the 8.5010 c~bohydrate content and 
a final M, of 175000, the IT1 molecule is assumed 
to be tentatively comprised of one heavy (90 kDa) 
and two light (40 kDa) chains, which is also consis- 
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tent with the higher synthesis level for the light 
chain as compared to the heavy one. As yet, the 
assumption of a single polypeptide chain in the 
180-kDa IT1 relied upon the behaviour or IT1 in 
dissociating/reducing media, as neither SDS nor 
beta-mercaptoethanol disrupts the molecule into 
smaller proteins [ 1,9]. A urea-SDS-beta-mercap- 
toethanol mixture is likewise without effect (not 
detailed). This suggests that very strong inter-chain 
linkages are involved in the model proposed here; 
their nature remains to be elucidated. The present 
model of the 180-kDa IT1 contains one or more 
light chains; i.e., UID-like protein sequences. As 
UID displays 4 trypsin inhibitory sites [IO], this 
raises the question as to whether several inhibitory 
sites are present in the 180-kDa IT1 molecule; the 
1: 1 stoichiometry published for 180-kDa IT1 and 
trypsin [ 181 leads us to consider that some sites 
would then remain inactive because of steric hin- 
drance or oxidation of amino acids. 
UID and serum IT1 derivatives do not react with 
anti-180-kDa IT1 anti-serum which binds the 
95kDa polypeptide. Therefore, the latter is found 
exclusively as a component of the 180-kDA IT1 
and all IT1 derivatives originate from the 40-kDa 
chain-encoding mRNA population. Derivative 
heterogeneity in serum may result from poly- 
merization and/or enzyme complexation. This pic- 
ture argues against the 180-kDa IT1 being a pro- 
inhibitor, unless it is assumed that heavy-chain 
clearance occurs at a very high rate immediately 
after IT1 fragmentation, which seems unlikely. 
The observation of an increased level of serum IT1 
derivatives in inflammation has been attributed by 
others to accelerated fragmentation of the 180-kDa 
IT1 [3]. In contrast, we recently confirmed the in- 
crease in IT1 derivative during inflammation but 
observed no concomitant decrease in the 180-kDa 
ITI; we then hypothesized a discrete synthesis of 
the 180-kDa IT1 and its derivatives [lo]. These 
results are consistent with such a process as two 
different mRNAs would enable the cell to syn- 
thesize heavy and light chains simultaneously, part 
of the latter being excreted as such. In this respect, 
the unbalanced light and heavy chain syntheses 
observed from in vitro mRNA translation could 
correspond to the very high levels of ITI-derivativ- 
es consistenly found in baboon sera. Finally this 
study demonstrates that heptocytes ynthesize ITI. 
Analysis of mRNAs obtained from non-hepatic 
tissues should clarify the origin of pulmonary and 
urinary ITI-related inhibitors which may be syn- 
thesized in loco. 
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